Partnership and Manufacturing Agreement - Plus Therapeutics and SpectronRx signed a Manufacturing Services Agreement (MSA) for the production of Rhenium (186Re) Obisbemeda, a targeted radiotherapy for CNS cancers [1] - The partnership aims to enhance supply chain redundancy and meet the demands of late-stage clinical trials and future commercial needs [3] - SpectronRx will utilize its state-of-the-art facilities, including over 170,000 sq ft of radiopharmaceutical contract development and manufacturing space, to produce Rhenium (186Re) Obisbemeda [2] Rhenium (186Re) Obisbemeda - Rhenium (186Re) Obisbemeda is a novel injectable radiotherapy designed to deliver targeted high-dose radiation to CNS tumors, potentially reducing off-target risks and improving patient outcomes [4] - The therapy is being evaluated in the ReSPECT-GBM and ReSPECT-LM clinical trials for recurrent glioblastoma and leptomeningeal metastases, supported by a $17.6M grant from CPRIT [4] - Rhenium-186 is an ideal radioisotope for CNS therapeutic applications due to its short half-life, beta energy for destroying cancerous tissue, and gamma energy for real-time imaging [4] Company Overviews - Plus Therapeutics is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for CNS cancers, with lead programs in recurrent glioblastoma and leptomeningeal metastases [5] - SpectronRx is a radiopharmaceutical developer and manufacturer with expertise in radiopharmaceutical contract development, manufacturing, and isotope production, supplying products to 29 countries [6][8] - SpectronRx has over 170,000 sq ft of production space, 150 employees, and facilities in Indiana, Connecticut, and Europe, enabling it to condense timelines for bringing new medicines to market [7][8]
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership